

C4 Imaging Signs SIRIUS™ MRI MARKER Loading Services Agreement with AnazaoHealth Corporation

Houston, Texas, (March 31, 2014) – C4 Imaging LLC is pleased to announce the signing of a loading services agreement for its first product, the Sirius™ MRI Marker, with AnazaoHealth Corporation. The novel positive-signal, MRI Marker [1] will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance (MR) imaging procedure.

C4 Imaging will partner with Florida-based AnazaoHealth Corporation, a leading provider of patient-specific prescription-loaded brachytherapy products for treating prostate cancer. Under the agreement AnazaoHealth will load the Sirius™ MRI Marker alongside seeds into brachytherapy strands and needles according to a physician prescription tailored to each individual patient. “AnazaoHealth has a long-standing reputation for quality and service to the prescription-loaded prostate brachytherapy market,” said Andrew Bright, President and CEO of C4 Imaging. “We are delighted to partner with them, allowing broad access to our Sirius™ MRI Marker for prostate brachytherapy physicians and seed vendors alike.”

Brachytherapy, or radioactive seed implantation, is a standard option for the curative treatment of prostate cancer. Brachytherapy involves implanting around 100 seeds into the prostate. Its popularity has increased due to its effectiveness, convenience, relatively low incidence of erectile dysfunction, and minimal invasiveness [2]. Radiation released from the seeds penetrates the surrounding prostate tissue at a limited distance, with most of the radiation concentrated within the prostate. Outcomes after brachytherapy can be excellent but depend greatly on the quality of the implant: 8-year prostate-specific antigen (PSA) relapse-free survival rates of 93% for high-quality implants vs. 76% for low-quality ones have been reported [3].

“While C4 Imaging is a new entrant into the US prostate brachytherapy market the company’s management team is highly experienced in this area”, said Chris A Arnette, President and Chief Operating Officer of AnazaoHealth Corporation. “We are excited to partner with them as they introduce the Sirius™ MRI Marker. Sirius™ has the potential to revolutionize prostate brachytherapy; with improved MRI based post-implant imaging leading to further increases in the quality of this highly-effective and cost-effective treatment option.”

About C4 IMAGING

C4 Imaging LLC develops medical devices that enable clinicians to more accurately perform image-guided procedures. The company’s core proprietary technology, C4, has been developed as Sirius™ the first commercially available Positive-Signal MRI Marker. Further information is available at www.c4imaging.com

For further information please contact:

Andrew Bright

President and CEO

C4 Imaging

Tel: 609 933 5895

abright@c4imaging.com

About AnazaoHealth

Since 1997, AnazaoHealth Corporation has created innovative patient specific preparations serving the nuclear medicine, pain management and custom pharmacy markets, as well as providing drugs used in clinical trials. AnazaoHealth are headquartered in Tampa, FL with an additional facility in Las Vegas, NV.

AnazaoHealth is a pharmacy that specializes in compounding sterile preparations and is fully licensed to provide nuclear, radioactive materials and DEA controlled substances in all 50 states. AnazaoHealth is both 797 and PCAB accredited.

Copyright © 2014

Sirius is a trademark of C4 Imaging.

References

1. Frank SJ, et al. Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy. *Med Dosim.* 2011 36(2): 200-205.
2. Frank SJ, et al. American College of Radiology Appropriateness Criteria Permanent Source Brachytherapy for Prostate Cancer. *Brachytherapy.* 2011; 10(5): 357-362.
3. Zelefsky MJ, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. *Int. J. Radiat. Oncol. Biol. Phys.* 2007; 67(2): 327-333.